ANALYSIS: Myriad, Mayo fuel US biotech patent rejections
This article was originally published in Clinica
Executive Summary
Rejections by the US Patent and Trademark Office (US PTO) of applications for biotechnology-related inventions appear to significantly be on the rise after new examination guidelines were put in place following the Supreme Court's rulings in Association for Molecular Pathology v Myriad Genetics and Mayo Collaborative Services v Prometheus Laboratories – two decisions that sent shockwaves through the industry – according to a new report.